Back to Search

Phase 1/2a Open-label Trial to Evaluate the Safety, Tolerability, PK, PD, Immunogenicity, and Antitumor Activity of LAVA-1207, a PSMA-targeting Bispecific ??-T Cell Engager, in Patients With Therapy Refractory mCRPC

  • Protocol Number: 202201008
  • Principal Investigator: Picus, Joel
  • Cancer Types: GU: Bladder, Kidney, Prostate, Testicular

For more information on this trial, contact us here:

[email protected]

Brief Summary

Protocol Interventions